Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19124354 | 0.92 | ADORA3 (0.48) | ADORA3ADORA2AADORA1MAPT | |
| SCHEMBL19125189 | 0.85 | ADORA3 (0.67) | ADORA3ADORA2AADORA1 | |
| SCHEMBL19126126 | 0.84 | ADORA3 (0.48) | ADORA3ADORA2AADORA1MAPT | |
| SCHEMBL19125186 | 0.82 | ADORA3 (0.47) | ADORA3ADORA2AMAPT | |
| SCHEMBL19124607 | 0.80 | ADORA3 (0.75) | ADORA3ADORA2AADORA1 | |
| SCHEMBL19124128 | 0.79 | ADORA3 (0.45) | ADORA3ADORA2AMAPT | |
| SCHEMBL19124234 | 0.78 | ADORA3 (0.49) | ADORA3ADORA2AADORA1 | |
| SCHEMBL19124655 | 0.77 | ADORA3 (0.66) | ADORA3ADORA2A | |
| SCHEMBL19125063 | 0.75 | ADORA3 (0.66) | ADORA3ADORA2A | |
| SCHEMBL19124216 | 0.72 | ADORA3 (0.56) | ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC. (KR) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885MEN1 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.